Literature DB >> 16107832

Unravelling hepatitis C virus replication from genome to function.

Brett D Lindenbach1, Charles M Rice.   

Abstract

Since the discovery of the hepatitis C virus over 15 years ago, scientists have raced to develop diagnostics, study the virus and find new therapies. Yet virtually every attempt to dissect this pathogen has met with roadblocks that impeded progress. Its replication was restricted to humans or experimentally infected chimpanzees, and efficient growth of the virus in cell culture failed until very recently. Nevertheless hard-fought progress has been made and the first wave of antiviral drugs is entering clinical trials.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16107832     DOI： 10.1038/nature04077

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


  279 in total

1.  Poly(C)-binding protein 2 interacts with sequences required for viral replication in the hepatitis C virus (HCV) 5' untranslated region and directs HCV RNA replication through circularizing the viral genome.

Authors:  Linya Wang; King-Song Jeng; Michael M C Lai
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  The role of PERK and GCN2 in basal and hydrogen peroxide-regulated translation from the hepatitis C virus internal ribosome entry site.

Authors:  Samantha C Jack; Shiu-Wan Chan
Journal:  Virus Genes       Date:  2011-06-03       Impact factor: 2.332

3.  Activity-based protein profiling identifies a host enzyme, carboxylesterase 1, which is differentially active during hepatitis C virus replication.

Authors:  David R Blais; Rodney K Lyn; Michael A Joyce; Yanouchka Rouleau; Rineke Steenbergen; Nicola Barsby; Lin-Fu Zhu; Adrian F Pegoraro; Albert Stolow; David L Tyrrell; John Paul Pezacki
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

4.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

5.  Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.

Authors:  Naushad Ali; Heba Allam; Randal May; Sripathi M Sureban; Michael S Bronze; Ted Bader; Shahid Umar; Srikant Anant; Courtney W Houchen
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 6.  A perspective on modelling hepatitis C virus infection.

Authors:  J Guedj; L Rong; H Dahari; A S Perelson
Journal:  J Viral Hepat       Date:  2010-08-15       Impact factor: 3.728

7.  In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.

Authors:  Tse-I Lin; Oliver Lenz; Gregory Fanning; Thierry Verbinnen; Frédéric Delouvroy; Annick Scholliers; Katrien Vermeiren; Asa Rosenquist; Michael Edlund; Bertil Samuelsson; Lotta Vrang; Herman de Kock; Piet Wigerinck; Pierre Raboisson; Kenneth Simmen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

8.  Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.

Authors:  Yueh-Ming Loo; David M Owen; Kui Li; Andrea K Erickson; Cynthia L Johnson; Penny M Fish; D Spencer Carney; Ting Wang; Hisashi Ishida; Mitsutoshi Yoneyama; Takashi Fujita; Takeshi Saito; William M Lee; Curt H Hagedorn; Daryl T-Y Lau; Steven A Weinman; Stanley M Lemon; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

9.  Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling.

Authors:  Libin Rong; Jeremie Guedj; Harel Dahari; Alan S Perelson
Journal:  Antivir Ther       Date:  2014-01-16

10.  Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death.

Authors:  Guaniri Mateu; Ruben O Donis; Takaji Wakita; Jens Bukh; Arash Grakoui
Journal:  Virology       Date:  2008-05-02       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.